| 1 |
Strengths and Weaknesses of the Pharmacovigilance Systems in Three Arab Countries: A Mixed-Methods Study Using the WHO Pharmacovigilance Indicators |
|
| | Hamza Garashi, Douglas Steinke, Ellen Schafheutle | | | International Journal of Environmental Research and Public Health. 2022; 19(5): 2518 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Stimulated adverse drug reaction reporting in pharmacovigilance: Indian perspectives |
|
| | Anusha Thota, Siddharth Sarkar, Snehil Guptha, Prasad Thota | | | Journal of Pharmacovigilance and Drug Research. 2021; 2(2): 13 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Medical students as adverse drug event managers, learning about side effects while improving their reporting in clinical practice |
|
| | M. Reumerman, J. Tichelaar, M.C. Richir, M.A. van Agtmael | | | Naunyn-Schmiedeberg's Archives of Pharmacology. 2021; 394(7): 1467 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
A systematic review on learning outcomes of pharmacovigilance issues: Undergraduates of pharmacy |
|
| | Carla Pires | | | International Journal of Educational Research. 2021; 109: 101845 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Stakeholders’ knowledge, attitudes and practices to pharmacovigilance and adverse drug reaction reporting in clinical trials: a mixed methods study |
|
| | David O. Riordan, Mary Kinane, Kieran A. Walsh, Frances Shiely, Joe Eustace, Margaret Bermingham | | | European Journal of Clinical Pharmacology. 2020; 76(10): 1363 | | | [Pubmed] [Google Scholar] [DOI] | |
|
